Translational Development Acquisition Corp. (TDAC)

TDAC Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	0.44	0	0
Cash & Short-Term Investments	0.44	0	0
Cash Growth	21581.05%	-9.17%	-
Prepaid Expenses	0.21	-	0.05
Total Current Assets	0.65	0	0.05
Long-Term Deferred Charges	-	-	0.38
Other Long-Term Assets	174.35	-	-
Total Assets	175	0	0.44
Accounts Payable	0.02	0	-
Accrued Expenses	0.19	0.16	0.2
Short-Term Debt	-	0.35	0.26
Other Current Liabilities	0	-	-0
Total Current Liabilities	0.21	0.51	0.46
Other Long-Term Liabilities	180.39	-	-
Total Liabilities	180.6	0.51	0.46
Common Stock	0	0	0
Additional Paid-In Capital	-	0.02	0.02
Retained Earnings	-5.6	-0.53	-0.05
Shareholders' Equity	-5.6	-0.51	-0.02
Total Liabilities & Equity	175	0	0.44
Total Debt	-	0.35	0.26
Net Cash (Debt)	0.44	-0.35	-0.26
Net Cash Per Share	0.10	-0.09	-0.06
Filing Date Shares Outstanding	21.91	4.66	4.05
Total Common Shares Outstanding	21.91	4.66	4.05
Working Capital	0.44	-0.51	-0.41
Book Value Per Share	-0.26	-0.11	-0.01
Tangible Book Value	-5.6	-0.51	-0.02
Tangible Book Value Per Share	-0.26	-0.11	-0.01

Updated Nov 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q